NephroGenex (NRX) Misses Q2 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
NephroGenex Reports Second Quarter 2015 Financial Results
August 12, 2015 4:12 PM EDTConference call and webcast to be held Thursday, August 13, 2015 at 8 a.m. Eastern
RALEIGH, N.C.--(BUSINESS WIRE)-- NephroGenex, Inc. (Nasdaq: NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today reported financial results and business highlights for the second quarter ended June 30, 2015.
During the second quarter of 2015, we made substantial gains in advancing our Phase 3 study of oral Pyridorin to treat diabetic nephropathy, said Chief Executive Officer Pierre Legault. With more than 120 clinical sites now participating in our PIONEER trial, we... More
